During the Society of American Gastrointestinal and Endoscopy Surgeons 2014 meeting, Medigus presented a study on its MUSE system.
The study examined the system's efficacy as a trans-oral treatment for gastroesophageal reflux disease. The study found:
• 85 percent of GERD patients reduced proton pump inhibitor use by 50 percent or more
• Of these patients, 65 percent were able to eliminate medication use after six months
• 73 percent of patients reported improved quality of life scores of 50 percent or more
More Articles on Gastroenterology:
Adenoma Detection Rate: Lowering Colorectal Cancer Risk
12 Gastroenterologist Moves & Honors
Defining Leadership in the GI Field: 2 Gastroenterologists Discuss Their Strategies
The study examined the system's efficacy as a trans-oral treatment for gastroesophageal reflux disease. The study found:
• 85 percent of GERD patients reduced proton pump inhibitor use by 50 percent or more
• Of these patients, 65 percent were able to eliminate medication use after six months
• 73 percent of patients reported improved quality of life scores of 50 percent or more
More Articles on Gastroenterology:
Adenoma Detection Rate: Lowering Colorectal Cancer Risk
12 Gastroenterologist Moves & Honors
Defining Leadership in the GI Field: 2 Gastroenterologists Discuss Their Strategies